E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Metastatic pancreatic cancer |
|
E.1.1.1 | Medical condition in easily understood language |
Pancreatic cancer that has spread to other areas of the body |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Cancer [C04] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 14.1 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10033605 |
E.1.2 | Term | Pancreatic cancer metastatic |
E.1.2 | System Organ Class | 100000004864 |
|
E.1.3 | Condition being studied is a rare disease | Yes |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To compare the efficacy of CO-1.01 and gemcitabine in patients with metastatic pancreatic adenocarcinoma and low human equilibrative nucleoside transporter 1 (hENT1) expression |
|
E.2.2 | Secondary objectives of the trial |
• To compare the efficacy of CO-1.01 and gemcitabine in patients with metastatic pancreatic adenocarcinoma and known hENT1 status (all patients and high hENT1 expression).
• To compare the tolerability and toxicity of CO-1.01 with gemcitabine.
• To compare changes in pain severity in patients receiving CO-1.01 and gemcitabine.
• To compare changes in health status in patients receiving CO-1.01 and gemcitabine.
• To perform sparse PK sampling in patients taking CO-1.01 to contribute towards development of a population PK model of CO-1.01.
• To evaluate the clinical utility of the hENT1 diagnostic test. |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
Patients are eligible for the study if all of the following criteria are met:
• Metastatic pancreatic ductal adenocarcinoma (i.e., Stage 4).
• Histological/cytological confirmation of metastatic tissue (not primary tumor) by a central pathology laboratory (H&E stain) to ensure sufficient material is available for later hENT1 analysis.
− Biopsy from metastases must be obtained ≥3 months after adjuvant chemotherapy (if applicable).
− Paraffin block or freshly fixed tissue sufficient for preparing ≥6 unstained slides for central storage and subsequent hENT1 analysis is required.
• Adjuvant chemotherapy/radiotherapy (if administered) ≥6 months prior to randomization.
• Palliative radiotherapy (if administered) ≥1 month prior to randomization.
• CT scan ≤30 days prior to randomization.
• Performance Status (ECOG) 0 or 1.
• Estimated life expectancy ≥12 weeks.
• Age ≥18 years.
• Adequate hematological and biological function, which is defined as the following:
Bone marrow function
− Neutrophils ≥1.5 × 10 to the power of 9/L
− Platelets >100.0 × 10 to the power of 9/L
− Hemoglobin ≥9 g/dL
Hepatic function
− AST ≤2.5 × upper limit of normal (ULN); if liver metastases, ≤5 × ULN
− Bilirubin ≤1.5 times ULN; if liver metastases, ≤3 × ULN
− Albumin >3 g/dL
− PT/PTT within 10% ULN
Renal function
− Serum creatinine ≤1.5 × ULN
• Written consent on an IRB/IEC-approved Informed Consent Form prior to any study-specific evaluation. |
|
E.4 | Principal exclusion criteria |
Patients are excluded from the study if any of the following criteria are met:
• Prior palliative chemotherapy for pancreatic cancer.
• Radical pancreatic resections (e.g., Whipple procedure) are not allowed < 6 months prior to randomization. Exploratory laparotomy, palliative (e.g., bypass) surgery, or other procedures (e.g., stents) are not allowed <14 days prior to randomization. In both cases the patient must be sufficiently recovered and stable.
• Symptomatic brain metastases.
• Participation in other investigational drug clinical studies ≤30 days prior to randomization.
• Concomitant treatment with prohibited medications (e.g., concurrent anticancer therapy including other chemotherapy, radiation, hormonal treatment, or immunotherapy) ≤30 days prior to randomization.
• History of allergy to gemcitabine or eggs.
• Presence of any serious or unstable concomitant systemic disorder incompatible with the clinical study (e.g., substance abuse, uncontrolled intercurrent illness including active infection, arterial thrombosis, symptomatic pulmonary embolism).
• Any disorder that would hamper protocol compliance.
• Prior nonpancreatic malignancy treated with chemotherapy. Prior malignancies treated with surgery or radiotherapy alone must be in remission ≥3 years. Prior malignancies allowed irrespective of when they occurred are in situ carcinoma of the cervix, in situ ductal breast cancer, low-grade local bladder cancer, and nonmelanotic
skin cancer.
• Females who are pregnant or breastfeeding.
• Refusal to use adequate contraception for fertile patients (females and males during the study and for 6 months after the last protocol-specified treatment). Adequate forms of contraception are docuble-barrier methods (condoms or diaphragm with spermicidal jelly or foam); oral, depot, or injectible contraceptives, interuterine devices; tubal ligation.
• Any other reason the investigator considers the patient should not participate in the study. |
|
E.5 End points |
E.5.1 | Primary end point(s) |
The overall survival (OS) in patients with low hENT1 expression
|
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
The primary endpoint analysis will take place when 90 events of death
have been observed in the hENT1-low patients. |
|
E.5.2 | Secondary end point(s) |
• OS in all patients and patients with high hENT1 expression
• Objective tumor response rate (ORR), duration of response, and progression free survival (PFS) in patients with measurable/evaluable disease, using RECIST 1.1.
• CA 19-9 velocity and response rate.
• Drug tolerability and toxicity using clinical AE monitoring, clinical laboratory testing, ECG outcomes, and dose modifications of protocol-specified treatment
• Change from baseline in pain severity measured by the worst pain on the Brief Pain Inventory (BPI) short form.
• Change from baseline in health status measured by the European Quality of Life-5 Dimension (EQ-5D) instrument and European Quality Visual Analog Scale (EQ VAS)
• PK profile of CO-1.01 based on sparse sampling. |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
The secondary analyses will occur when 90 events of death have been
observed in the hENT1-low patients. AEs will be assessed from the time informed consent (IC) is obtained through 28 days after the last
protocol-specified treatment administration. |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | Yes |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | Yes |
E.6.11 | Pharmacogenomic | Yes |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | Yes |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 2 |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 3 |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 31 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
Argentina |
Australia |
Brazil |
Canada |
Russian Federation |
Ukraine |
United States |
|
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
The study will close once all CO-1.01 patients have either completed participation or have transferred to a locally approved treatment access program in accordance with relevant local regulations. |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 2 |
E.8.9.1 | In the Member State concerned months | 4 |
E.8.9.1 | In the Member State concerned days | 0 |
E.8.9.2 | In all countries concerned by the trial years | 2 |
E.8.9.2 | In all countries concerned by the trial months | 4 |
E.8.9.2 | In all countries concerned by the trial days | 0 |